Acute promyelocytic leukemia (APL): Remaining challenges towards a cure for all Review

   


Authors: Stahl, M.; Tallman, M. S.
Review Title: Acute promyelocytic leukemia (APL): Remaining challenges towards a cure for all
Abstract: The application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) has revolutionized the treatment of acute promyelocytic leukemia (APL). More than 80–90% of patients are expected to be cured with a combination of ATRA, ATO and/or chemotherapy. In this review, we focus on the remaining obstacles to a cure for all patients with APL. We review the issue of early death and coagulopathy and discuss the particular challenges in the care of patients with high-risk APL and patients with relapsed APL. We also give recommendations and highlight ongoing efforts to improve the persistently high early death rate and the outcomes of high risk and relapsed APL patients. © 2019, © 2019 Informa UK Limited, trading as Taylor & Francis Group.
Keywords: apl; atra; cure
Journal Title: Leukemia and Lymphoma
Volume: 60
Issue: 13
ISSN: 1042-8194
Publisher: Taylor & Francis Group  
Date Published: 2019-01-01
Start Page: 3107
End Page: 3115
Language: English
DOI: 10.1080/10428194.2019.1613540
PUBMED: 31842650
PROVIDER: scopus
PMCID: PMC7479633
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076917095&doi=10.1080%2f10428194.2019.1613540&partnerID=40&md5=a1eba4ca6707ecb054e608f34d7d0ae7
Notes: Review -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Martin Stuart Tallman
    649 Tallman
  2. Maximilian Stahl
    42 Stahl
Related MSK Work